Revenue growth holds, margins expand despite wage hikes
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Q1 guided for high-single-digit FY27 growth, wage headwinds. Q2 delivered 15% YoY growth, offset wage impact. No numeric guidance provided; track record intact.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 delivered 15% YoY revenue growth and margin expansion (70 bps EBITDA) despite significant wage hikes, powered by operational leverage and new strategic automotive OEM deals. Key risk: Europe remains uncertain with large OEM decisions delayed; near-term upside capped until deal ramps prove material over next 2-3 quarters.
₹1055.7 Cr
Revenue · +15% YoY₹170.3 Cr
Reported PAT · +10% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue growth 2.3% constant currency despite wage hikes
METReported ₹1055.7 Cr; YoY +15%, QoQ +3.4% in INR. Constant-currency strip is realistic.
EBITDA margin expanded 70 bps QoQ to 21.9% despite wage hikes
METReported OPM 21.9%, NPM 15.6%. Margin expansion over Q1 corroborated by 70 bps EBITDA claim.
Transportation vertical 2% QoQ growth; media 3.4% QoQ; healthcare 3.5% QoQ
METDelivered numbers support broad-based growth across segments. No contradiction evident.
Large multi-year strategic deals with automotive OEMs and aerospace suppliers won
METDeal wins mentioned (Sarfia Aviation, global aerospace supplier, global tech leader for GenAI). Still early-stage ramp (2-3 quarters to full scale).
Utilization 78%; headroom for leverage
METCFO disclosed 78% utilization vs ~81-82% pre-COVID peak. Direct quote supports claim.
Earnings quality
What changed since the last call
Wage hike impact realized; offset mastered
NeutralQ1 flagged wage headwind; Q2 delivered 70 bps EBITDA expansion via operational leverage. Change: headwind absorbed faster than anticipated.
Strategic AI engagement announced
NewGenAI partnership with global tech leader announced. Positions for AI-first vertical; margins TBD as offering scales.
Aerospace & defense inroads concrete
UpgradeSarfia Aviation collaboration and global aerospace supplier deals signed. Prior: aspiration; now: 60-70% YoY growth on emerging segment.
Europe demand still uncertain
DowngradeQ1 flagged Europe soft; Q2 confirms delay in large OEM decision-making persists. No near-term recovery visibility.
The Q&A
Analysts pressed hard on growth sustainability (Bhavik), deal ramp velocity (Sulabh, Amit), wage leverage limits (Rishi), customer concentration (Sankaranarayanan, Ankur), Europe trajectory (Rohan). Management held firm on growth momentum, disclosed utilization 78% (room to grow), clarified multi-year deals and margin bridge, acknowledged Europe uncertain but not catastrophic. No evasion detected.
Growth sustainability — Bhavik Mehta, JP Morgan
AnsweredGrowth across all verticals. Deal ramp-ups are part of model; reps time to scale (2-3 quarters). One-time FX and operational benefits reversing; operational leverage continuing.
Employee cost trajectory — Rishi Mody, Mody Advisory
Wage hikes one-time and structural; done for this year. Utilization 78% vs 81-82% pre-COVID; room to improve. Pyramid management active; expect benefit H2 H1.
Deal ramp velocity — Sulabh Govila, Morgan Stanley
AnsweredDeals 2-3 quarters to full scale. Multi-year contracts protect revenue base. Supplier leakage normalizing as automotive OEM concentration drops.
AI investment ROI — Shivam, DT
PartialAI budgets enterprise-wide transformation focus, not R&D only. Pragmatism emerging on ROI; companies demanding value linkage.
New deal margin profile — Amit Chandra, HDFC
AnsweredNew deals reasonably flat margin; improvement via pyramid optimization and utilization leverage over 2-3 quarters. No near-term margin accretion from new deals alone.
Guidance policy — Gaurav Ashok Bhanshali, Augmont
AnsweredNo formal guidance as policy. H2 expected better than H1; gradual calibrated improvement, not a jump.
New growth vectors scale — Sankaranarayanan S, ithought PMS
PartialAerospace/defense 60-70% YoY growth on small base. Still nascent. Diversification happening; automotive dominance persists but declining share over time.
Healthcare concentration risk — Ankur Pant, IIFL
AnsweredCustomer diversification improving; large deals announced (Bayer, Teruno, Japanese deals). Revenue base now broader, less US-centric. H2 > H1 expected.
Contract margins and onsite-offshore — Mayank Kumar, Prasoon Exponentials
AnsweredDon't distinguish by contract type; focus on customer value add. Onsite-offshore ratio ~25:75. Room to optimize.
Europe macro and tariff risk — Rohan Nagpal, Helios Capital
AnsweredEurope still uncertain; OEM decisions slow. Chinese tariffs not expected to change trajectory near-term; systemic OEM cost issues take time.
Guidance
No formal FY27 revenue target; high-single-digit aspiration stated in Q1
MediumQ1 guidance 'aspire for high-single-digit FY27 growth.' Q2 delivered 15% YoY, validating execution but below FY27 full-year run-rate if Q3-Q4 moderate. Management now confident on momentum.
Gradual calibrated EBITDA margin improvement H2; operational leverage to continue
MediumExpect 2-3 quarter progressive improvement via utilization, pyramid optimization, wage hike absorption complete. Not expecting sharp inflection; margin at 21.9% is baseline.
Risks the call surfaced
Europe geographic drag
MediumEurope OEM decisions slow; automotive-heavy region faces cost pressures and electrification uncertainty. Deal closure timeline unclear.
Deal ramp-up execution risk
MediumLarge automotive OEM and aerospace deals still 2-3 quarters from full ramp. Revenue timing and margin accretion could slip if resource constraints or customer ramps delayed.
Customer concentration (Tata Motors, JLR)
MediumTata Motors and JLR represent material revenue; JLR acknowledged facing internal challenges (cost, EV transition). Growth in both is material but conditional on their success.
Margin leverage dependent on utilization
LowManagement's guidance for margin expansion relies on utilization improvement from 78% toward 81-82% and pyramid optimization. If deal ramps slip, utilization gains at risk.
Wage hike structural headwind
LowWage hikes implemented are structural (not one-time). If salary inflation continues, operational leverage gains could plateau or reverse.
Management
Score 7/10. Clear on metrics, segment-level detail. Transparent on headwinds (Europe soft, JLR challenges, wage hike absorption). Refuses to give numerical guidance (policy), which is conservative. Delivered 15% YoY revenue growth against 70 bps margin expansion despite wage hikes. Healthcare and aerospace deals executed. Q1 wage headwind predictions validated by Q2 operational leverage. Track record intact.
1 · Q3 FY27
Aerospace, defense, battery verticals scale-up traction
2 · Q3 FY27
Healthcare vertical rebound (management expects H2 > H1)
3 · Q4 FY27
Automotive OEM large deal ramp-up full stage (2-3Q out)
Key risk: Europe remains uncertain with large OEM decisions delayed; near-term upside capped until deal ramps prove material over next 2-3 quarters.
Informational and educational content only. Not investment advice.